SMStephen R. Morairty

Stephen R. Morairty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephen R. Morairty has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RO4938581, a GABAA-α5 negative allosteric modulator rescued behavioral and EEG phenotypes of a mouse model of Dup15q syndrome

    by Ryoko Nakagawa, Francesca Nani, Joerg F. Hipp, Michael Honer, Frederic Knoflach, Rodolfo Gasser, Laurence Ozmen, Kota Tamada, Fatiha Fjeldskaar, Livia Takacs, et al.

    We investigated the correlation between increased gene copy number of gamma aminobutyric acid type A (GABAA) receptor α5-containing subunits and electrophysiological and behavioral phenotypes in a mouse model of Dup15q syndrome (15q dup) and tested the hypothesis that selectively inhibiting the activity of GABAA-α5 receptors may have therapeutic effects. Dup15q syndrome is a rare neurodevelopmental disorder caused by copy number gains of the 15q11.2-q13.1 chromosomal region, which includes UBE3A and a cluster of three genes (GABRA5, GABRB3, and GABRG3) encoding GABAA receptor subunits, all of which are critical for neural development and function. Most affected children display hypotonia, motor delays, intellectual disability, and epilepsy, as well as a characteristic electroencephalography (EEG) beta-band phenotype. There is no disease-modifying therapy available. Autoradiography showed increased density of GABAA-α5 receptors in the brains of 15q dup mice, while electrophysiology revealed enhanced GABAergic transmission in hippocampal slices from these mice. A GABAA-α5 negative allosteric modulator, RO4938581, decreased inhibitory synaptic charge transfer in 15q dup hippocampal slices. The behavioral analyses confirmed inflexibility in learning and abnormal social behaviors in 15q dup mice, and both phenotypes were normalized following chronic treatment with RO4938581. EEG recordings showed increased beta-power in 15q dup mice – which resembled the spectral signature of subjects with Dup15q – and was partially normalized following RO4938581 treatment. Our results suggest that excessive expression and function of the GABAA-α5 receptor subtype plays a key role in the pathophysiology of Dup15q and GABAA-α5 NAMs may represent a potential precision medicine therapeutic option.


  • Open Access

    Biological sex influences sleep phenotype in mice experiencing spontaneous opioid withdrawal

    by Ryan K. Tisdale, Yu Sun, Sunmee Park, Shun‐Chieh Ma, Meghan Haire, Giancarlo Allocca, Michael R. Bruchas, Stephen R. Morairty, Thomas S. Kilduff

    Summary: Aversive symptoms, including insomnia experienced during opioid withdrawal, are a major drive to relapse; however, withdrawal‐associated sleep symptomatology has been little explored in preclinical models. We describe here a model of opioid withdrawal in mice that resembles the sleep phenotype characteristic of withdrawal in humans. Male and female C57BL/6 mice were instrumented with telemeters to record electroencephalogram, electromyogram, activity and subcutaneous temperature. All mice received two treatments separated by a 16‐day washout period: (1) saline (volume: 10 ml kg−1); or (2) ascending doses of morphine (5, 10, 20, 40 and 80 mg kg−1; volume: 10 ml kg−1) for 5 days at Zeitgeber time 1 and Zeitgeber time 13. Recordings for the first 71 hr after treatment discontinuation (withdrawal days 1–3) and for 24 hr on withdrawal days 5 and 7 were scored for sleep/wake state, and sleep architecture and electroencephalogram spectral data were analysed. Morphine was acutely wake‐ and activity‐promoting, and non‐rapid eye movement and rapid eye movement sleep were increased during the dark phase on withdrawal day 2 in both sexes. While non‐rapid eye movement delta power (0.5–4.0 Hz), a measure of sleep intensity, was reduced during the light phase on withdrawal day 1 and the dark phase on withdrawal day 2 in both sexes, female mice also exhibited changes in the duration and the number of bouts of sleep/wake states. These observations of fragmented sleep on withdrawal days 1–3 suggest poorer sleep consolidation and a more pronounced withdrawal‐associated sleep phenotype in female than in male mice. These data may indicate a greater sensitivity to morphine, a more distinct aversive sleep phenotype and/or a faster escalation to dependence in female mice.


  • Open Access

    Evaluation of the efficacy of the hypocretin/orexin receptor agonists TAK‐925 and ARN‐776 in narcoleptic orexin/tTA; TetO‐DTA mice

    by Yu Sun, Alok Ranjan, Ryan Tisdale, Shun‐Chieh Ma, Sunmee Park, Meghan Haire, Jasmine Heu, Stephen R. Morairty, Xiaoyu Wang, Daniel M. Rosenbaum, et al.

    Summary: The sleep disorder narcolepsy, a hypocretin deficiency disorder thought to be due to degeneration of hypothalamic hypocretin/orexin neurons, is currently treated symptomatically. We evaluated the efficacy of two small molecule hypocretin/orexin receptor‐2 (HCRTR2) agonists in narcoleptic male orexin/tTA; TetO‐DTA mice. TAK‐925 (1–10 mg/kg, s.c.) and ARN‐776 (1–10 mg/kg, i.p.) were injected 15 min before dark onset in a repeated measures design. EEG, EMG, subcutaneous temperature (Tsc) and activity were recorded by telemetry; recordings for the first 6 h of the dark period were scored for sleep/wake and cataplexy. At all doses tested, TAK‐925 and ARN‐776 caused continuous wakefulness and eliminated sleep for the first hour. Both TAK‐925 and ARN‐776 caused dose‐related delays in NREM sleep onset. All doses of TAK‐925 and all but the lowest dose of ARN‐776 eliminated cataplexy during the first hour after treatment; the anti‐cataplectic effect of TAK‐925 persisted into the second hour for the highest dose. TAK‐925 and ARN‐776 also reduced the cumulative amount of cataplexy during the 6 h post‐dosing period. The acute increase in wakefulness produced by both HCRTR2 agonists was characterised by increased spectral power in the gamma EEG band. Although neither compound provoked a NREM sleep rebound, both compounds affected NREM EEG during the second hour post‐dosing. TAK‐925 and ARN‐776 also increased gross motor activity, running wheel activity, and Tsc, suggesting that the wake‐promoting and sleep‐suppressing activities of these compounds could be a consequence of hyperactivity. Nonetheless, the anti‐cataplectic activity of TAK‐925 and ARN‐776 is encouraging for the development of HCRTR2 agonists.


  • Open Access

    Evaluation of the Efficacy of the Hypocretin/orexin Receptor Agonists TAK-925 and ARN-776 in Narcoleptic Orexin/tTA; TetO-DTA Mice

    by Yu Sun, Alok Ranjan, Ryan Tisdale, Shun-Chieh Ma, Sunmee Park, Meghan Haire, Jasmine Heu, Stephen R. Morairty, Xiaoyu Wang, Daniel M. Rosenbaum, et al.

    The sleep disorder Narcolepsy, a hypocretin deficiency disorder thought to be due to degeneration of hypothalamic hypocretin/orexin neurons, is currently treated symptomatically. We evaluated the efficacy of two small molecule hypocretin/orexin receptor-2 (HCRTR2) agonists in narcoleptic male orexin/tTA; TetO-DTA mice. TAK- 925 (1-10 mg/kg, s.c.) and ARN-776 (1-10 mg/kg, i.p.) were injected 15 min before dark onset in a repeated measures design. EEG, EMG, subcutaneous temperature (T sc ) and activity were recorded by telemetry; recordings for the first 6-h of the dark period were scored for sleep/wake and cataplexy. At all doses tested, TAK-925 and ARN-776 caused continuous wakefulness and eliminated sleep for the first hour. Both TAK-925 and ARN-776 caused dose-related delays in NREM sleep onset. All doses of TAK-925 and all but the lowest dose of ARN-776 eliminated cataplexy during the first hour after treatment; the anti-cataplectic effect of TAK-925 persisted into the 2 nd hour for the highest dose. TAK-925 and ARN-776 also reduced the cumulative amount of cataplexy during the 6-h post-dosing period. The acute increase in wakefulness produced by both HCRTR2 agonists was characterized by increased spectral power in the gamma EEG band. Although neither compound provoked a NREM sleep rebound, both compounds affected NREM EEG during the 2 nd hour post-dosing. TAK-925 and ARN-776 also increased gross motor activity, running wheel activity and T sc , suggesting that the wake-promoting and sleep-suppressing activities of these compounds could be a consequence of hyperactivity. Nonetheless, the anti-cataplectic activity of TAK-925 and ARN-776 is encouraging for the development of HcrtR2 agonists.

  • Open Access

    The Development of Sleep/Wake Disruption and Cataplexy as Hypocretin/Orexin Neurons Degenerate in Male vs. Female Orexin/tTA; TetO-DTA Mice

    by Yu Sun, Ryan Tisdale, Sunmee Park, Shun-Chieh Ma, Jasmine Heu, Meghan Haire, Giancarlo Allocca, Akihiro Yamanaka, Stephen R. Morairty, Thomas S. Kilduff

    Narcolepsy Type 1 (NT1), a sleep disorder with similar prevalence in both sexes, is thought to be due to loss of the hypocretin/orexin (Hcrt) neurons. Several transgenic strains have been created to model this disorder and are increasingly being used for preclinical drug development and basic science studies, yet most studies have solely used male mice. We compared the development of narcoleptic symptomatology in male vs. female orexin-tTA; TetO-DTA mice, a model in which Hcrt neuron degeneration can be initiated by removal of doxycycline (DOX) from the diet. EEG, EMG, body temperature, gross motor activity and video recordings were conducted for 24-h at baseline and 1, 2, 4 and 6 weeks after DOX removal. Female DTA mice exhibited cataplexy, the pathognomonic symptom of NT1, by Week 1 in the DOX(-) condition but cataplexy was not consistently present in males until Week 2. By Week 2, both sexes showed an impaired ability to sustain long wake bouts during the active period, the murine equivalent of excessive daytime sleepiness in NT1. Body temperature appeared to be regulated at lower levels in both sexes as the Hcrt neurons degenerated. During degeneration, both sexes also exhibited the “Delta State”, characterized by sudden cessation of activity, high delta activity in the EEG, maintenance of muscle tone and posture, and the absence of phasic EMG activity. Since the phenotypes of the two sexes were indistinguishable by Week 6, we conclude that both sexes can be safely combined in future studies to reduce cost and animal use. Statement of Significance: Although narcolepsy is a disorder that affects both men and women with similar frequency, most basic research and preclinical development studies of sleep have utilized male experimental subjects. The identification of the hypocretin/orexin (Hcrt) neuron loss as the likely cause of human narcolepsy has led to the development of transgenic mouse strains that model this disorder. Here, we compare the emergence of narcoleptic symptoms in male vs. female bigenic orexin-tTA; TetO DTA mice, a state-of-the-art narcolepsy model in which degeneration of the Hcrt neurons can be triggered by dietary manipulation. We find that female mice develop the narcoleptic phenotype more rapidly than males but that both sexes are equally symptomatic by the end of the degeneration period.


  • Open Access

    Automated Sleep Stage Scoring Using k-Nearest Neighbors Classifier

    by Tamás Kiss, Stephen Morairty, Michael Schwartz, Thomas S.\ Kilduff, Derek L.\ Buhl, Dmitri Volfson


  • Open Access

    Early life diet alters sleep architecture following an acute stress: The potential role of milk oligosaccharides

    by Maciej Chichlowski, Stephen Morairty, Brian M. Berg

    Stress exposure can produce disruptions in the sleep cycle that may contribute to altered cognitive performance. Prebiotics can selectively enhance select gut microbial species that may promote favorable response to stressrobustness. Our previous studies showed that a milk oligosaccharide, sialyllactose, supported normal microbial communities (similar to non‐stressed animals) and behavioral responses during stressor exposure, potentially through effects on the gut microbiota–brain axis. The aim of the current study was to determine whether early life dietary oligosaccharides would modulate the sleep cycle and protect sleep architecture following stress. We hypothesized that diet containing a blend of prebiotics (galactooligosaccharides, GOS+polydextrose, PDX) and/or sialyllactose (Lacprodan SAL‐10 ® ; SL) would mitigate stress induced alterations of electrophysiological markers of sleep. Male Sprague Dawley rats (postnatal day (P)21) were placed on one of the experimental diets for 30d: a) SL [2.2g/kg], b)GOS+PDX [7g/kg each], c) GOS+PDX [7g/kg each] + SL [2.2g/kg] or d) Control[cellulose as fiber source]. Telemetry devices were implanted on P64 to examine the differences in electroencephalograph (EEG) and electromyograph (EMG)measurements. Baseline 24h EEG recordings were performed on P84. Rats were exposed to an acute stressor (inescapable stress) on P85 in order to examine the potential protective effects of our experimental diets on stress‐induced sleep/wake cycle. An additional group of Control animals remained undisturbed(Control Unstressed). There were no differences in food intake and body weight gain among the groups. There was a normal EEG distribution of power across the 24 h period under baseline conditions for all diets. During baseline, GOS+PDX+SL group had decreased waketheta frequency compared to Control Unstressed group (PSupport or Funding Information Supported by Mead Johnson Nutrition.